AFT opening European office, signs new partners for MXG

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 18 November 2020

AFT opening European office, signs new partners for
Maxigesic IV and Oral range
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) announces the establishment of a new
subsidiary in Ireland, to drive the growth of the company’s products in Europe. It also
announces new licensing, distribution and supply agreements for:
• Maxigesic IV® in Ireland, and Thailand
• Maxigesic tablets in Greece, Pakistan and Ecuador
AFT has appointed Eddie Townslie, an experienced pharma executive, as the local
director of AFT Pharmaceuticals Europe. Mr Townslie is also Managing Director of
Ireland’s JED Pharma, which has been appointed the distributor of Maxigesic IV® in
Ireland. Prior to his current role Eddie was Export Director at diversified Irish
pharmaceutical group Pinewood Healthcare.
AFT Managing Director Dr Hartley Atkinson said the decision to open a European
representative office is a response to the ongoing growth in demand in the region for
its Maxigesic product range.
“Maxigesic IV
®
has now been submitted for registration in 27 European countries and
17 of these have been approved. As the number of registrations increases, so too will
the need for AFT to provide local support to Licensees and Distributors such as
regulatory services. Eddie is well placed to oversee this support and ensure AFT makes
the most of the significant opportunities we see in the region.”
According to an independent report by DelveInsight* published earlier this year,
Maxigesic in its various dose forms has the potential to generate sales of more than
$80 million across Europe’s major markets and the UK by 2028.
“We are also delighted to have secured agreements for Maxigesic IV
®
distribution with
Ireland’s Jed Pharmaceuticals for Ireland, along with Alliance Pharma in Thailand. We
have concluded licensing agreements with Switzerland’s Acino for Maxigesic oral
dose forms in Ecuador and Greek’s market leading Elpen Pharmaceuticals, along with
distribution agreements with the Karachi-based Excel Healthcare Laboratories for
Pakistan,” Dr Atkinson said.
“Acino distributes Maxigesic tablets in a broad range of countries including the
Central American Common Market (CACM), while the relationship with Excel
Healthcare Laboratories and Elpen is new.”

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

“We are delighted to continue to expand our partners for Maxigesic and Maxigesic
IV around the world with the focus now moving to completion of any remaining
regulatory actions and following that product launches,” Dr Atkinson said.
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical business with a broad range of
products, both developed itself and in-licensed from third parties. AFT’s products
cover all major pharmaceutical distribution channels: over-the-counter, prescription
and hospital. Historically, AFT’s home markets have been Australia, New Zealand and
South-East Asia. However, the company is out-licensing its own products to licensees
and distributors to sell in an increasing number of countries around the world. The
company’s intensive Research and Development program forms the basis of its
international sales strategy. For more information about the company, visit our website
www.aftpharm.com
.
About Elpen Pharmaceuticals
Elpen has a leading market position in Greek pharmaceuticals and when combined
with its highly successful salesforce and strong local relationships, is the partner of
choice for the Greek market. With expertise in international collaboration, Elpen
generates a significant portion of its annual turnover by promotion and sales of original
products entrusted to it by its multi-national partners. www.elpen.gr/en/

About Acino
Acino is a Swiss pharmaceutical company headquartered in Zurich, which has an in
depth-knowledge and competence in some of the most dynamic countries in the
world. It has a clear focus on selected markets in the Middle East, Africa, the CIS region
and Latin America, and is able to adapt its strategy to local needs. www.acino.swiss/

About JED Pharma
Jed Pharma is a Tipperary based pharmaceutical company that works to introduce
new brands and products to the Irish and UK market-place, leveraging its extensive
market network of private and public hospitals, direct healthcare providers, retail
pharmaceutical groups and independents outlets. www.jedpharma.com/


About Excel Healthcare Laboratories
Excel Healthcare Laboratories (Pvt) Ltd is incorporated in Pakistan and has as a key
focus branded and generic medicines with the aim of providing effective and
economical products for the entire community. www.xlhealthcarelab.com/

About Alliance Pharma

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

Alliance Pharma Co., is a local Thai pharmaceutical company with a strong
background in registration, distribution and sales of hospital medicines. By leveraging
their strong partnerships with hospital authorities and healthcare practitioners,
Alliance Pharma is well positioned to promote and establish branded
pharmaceuticals in the Thai market.
http://alliancepharma.co.th/index.html

References
*2020 Postoperative Pain Market Insights, Epidemiology and Market Forecast—2028.
Delveinsight.